- Original article
- Open Access
INFLOW study: a prospective observational study for assessment of indacaterol and other bronchodilators in symptomatic chronic obstructive pulmonary disease patients from Egypt
Egyptian Journal of Bronchology volume 11, pages 16–22 (2017)
The INdacaterol eFfectiveness and utiLizatiOn in COPD: real-World evaluation (INFLOW) study demonstrated significant improvements in health status with decreasing Clinical COPD Questionnaire (CCQ) scores in routine clinical practice with indacaterol (IND) and other bronchodilators from 12 countries in Asia, the Middle East and South Africa. Here, we report the data on real-life effectiveness of IND and other bronchodilators from Egypt.
In this 6-month, noninterventional, open-label study, patients were prescribed IND (150 or 300 μg) or other longacting β2-agonists (LABAs) or tiotropium (TIO) (monotherapy or in combination with IND or LABAs) as a part of routine medical care. Health status (CCQ scores), patient and physician satisfaction and safety were assessed.
Data were analysed from 152 patients (IND, n=88; IND+TIO, n=27; other-LABAs, n=6; TIO, n=10; and other- LABAs+TIO, n=21). At the end of the study, reduction from baseline CCQ total score was significant (P <0.0001) with IND and other treatments. Approximately 80% of patients were satisfied and physicians rated the current prescribed treatments as ‘good’ or ‘very good’ for over 70% of the patients. More than 80% of patients rated the indacaterol inhaler (Breezhaler) device as ‘easy’ and ‘very easy to use’, and physicians rated over 70% of patients as ‘clearly understood the use of the device’. No adverse events related to premature discontinuation were reported.
In real-world settings, IND as monotherapy or in combination with TIO was effective in improving the health status in COPD patients and is well tolerated. The majority of patients reported that the Breezhaler device was easy to use.
Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015
World Health Organization (WHO). Burden of COPD. Available from: http://www.who.int/respiratory/copd/burden/en/. 2016.
Mahler DA, Kerwin E, Ayers T, FowlerTaylor A, Maitra S, Thach C, et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/ glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 192:1068–1079
Uzaslan E, Mahboub B, Beji M, Nejjari C, Tageldin MA, Khan JA, et al. The burdenof chronicobstructive pulmonary diseaseintheMiddleEastandNorth Africa: results of the BREATHE study. Respir Med 2012; 106:(Suppl 2): S45–S59.
Tageldin MA, Nafti S, Khan JA, Nejjari C, Beji M, Mahboub B, et al., BREATHE Study Group Distribution of COPD-related symptoms in the Middle East and North Africa: results of the BREATHE study. Respir Med 2012; 106:(Suppl 2): S25–S32.
Sayiner A, Alzaabi A, Obeidat NM, Nejjari C, Beji M, Uzaslan E, et al. Attitudes and beliefs about COPD: data from the BREATHE study. Respir Med 2012; 106:(Suppl 2):S60–S74.
Azza F, Said AAE, Omran AA, Magdy ME, Saleeb MF. Prevalence and predictors of chronic obstructive pulmonary disease among high-risk Egyptians. Egypt J Bronchol 2015; 9:27–33.
Murphy L, Rennard S, Donohue J, Molimard M, Dahl R, Beeh KM, et al. Turning a molecule into a medicine: the development of indacaterol as a novel oncedaily bronchodilator treatment for patients with COPD. Drugs 2014; 74: 1635–1657.
Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis 2014; 9:215–228.
Siler TM, LaForce CF, Kianifard F, Williams J, Spangenthal S. Once-daily indacaterol 75 μg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients’ perceived onset of effect. Int J Chron Obstruct Pulmon Dis 2014; 9:919–925.
Mahler DA, Kerstjens HA, Donohue JF, Buhl R, Lawrence D, Altman P. Indacaterol vs tiotropium in COPD patients classified as GOLD A and B. Respir Med 2015; 109:1031–1039.
Mariani AW, Pêgo-Fernandes PM. Observational studies: why are they so important? Sao Paulo Med J 2014; 132:1–2.
Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2009.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
El-Sorougi, W.M., Abouelwafa, D. INFLOW study: a prospective observational study for assessment of indacaterol and other bronchodilators in symptomatic chronic obstructive pulmonary disease patients from Egypt. Egypt J Bronchol 11, 16–22 (2017). https://doi.org/10.4103/1687-8426.199000
- chronic obstructive pulmonary disease
- longacting bronchodilator
- real-life study